首页/数据集/Supplementary Tables 1-4 from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

Supplementary Tables 1-4 from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

NIAID Data Ecosystem2026-05-16 收录

乳腺癌内分泌治疗

ER信号通路

数据链接：

https://figshare.com/articles/dataset/Supplementary_Tables_1-4_from_ER_-Dependent_E2F_Transcription_Can_Mediate_Resistance_to_Estrogen_Deprivation_in_Human_Breast_Cancer/22528748 数据链接链接失效反馈

官方服务：

资源简介：

XLS file - 44K

应用场景：

创建时间：

2011-09-01

相关数据集

Sample Demographics.

癌症患者特征

乳腺癌内分泌治疗

Values are Mean (Standard Deviation), (Range). 1 M = one month post chemotherapy completion (or yoked intervals). aP value for one-way ANOVA with treatment groups for age, education, IQ, handedness,

NIAID Data Ecosystem100

SET ER/PR - A robust 18-gene Predictor for Sensitivity to Endocrine Therapy for Metastatic Breast Cancer. SET ER/PR - A robust 18-gene Predictor for Sensitivity to Endocrine Therapy for Metastatic Breast Cancer

乳腺癌内分泌治疗

肿瘤生物标志物

There is clinical need to predict sensitivity of metastatic hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer to endocrine therapy, and targeted RNA sequencing (RNAseq) offers diag

NIAID Data Ecosystem90

Additional file 8 of Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

乳腺癌内分泌治疗

药物反应基因表达

Additional file 8. List of 660 genes regulated by tamoxifen treatment in the MCF7LR tumors compared to letrozole-treated MCF7LR tumors.

Figshare2020-05-20 更新40

Low and High Dose Progestins Elicit Distinct Breast Cancer Biology. Homo sapiens

乳腺癌内分泌治疗

激素剂量效应

An incomplete understanding of dose-dependent progesterone receptor (PR) biology has led to the suboptimal exploitation of PR as a therapeutic target. While hormone replacement therapies (HRT) contain

NIAID Data Ecosystem90

Tamoxifen_Based_乳腺癌女性生殖系统超声队列研究数据

乳腺癌内分泌治疗

妇科超声监测

本数据集为基于超声的队列研究数据，研究他莫昔芬对乳腺癌女性生殖系统的影响。研究在巴格达三家肿瘤中心开展，纳入255例雌激素受体阳性乳腺癌患者（140例绝经前、115例绝经后），患者术后接受他莫昔芬辅助治疗至少3个月。数据记录患者年龄、绝经状态、合并症及用药情况，共包含1个文件。

海数据40